BRD4 and neoplasm: Specific BET inhibitors, including small molecule compounds that mimic the structure of acetylated lysine such as JQ1, have been developed as drugs to suppress tumour growth in several types of cancer.7,17 JQ1 binding to BRD4 prevents it from binding to acetylated histones, thus suppressing the excessive transcription of the oncogenes.